12/3
07:01 pm
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
11/29
12:31 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
Medium
Report
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
11/25
07:00 am
fhtx
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
11/17
06:19 am
fhtx
4D Molecular Therapeutics taps Kristian Humer as CFO [Seeking Alpha]
Low
Report
4D Molecular Therapeutics taps Kristian Humer as CFO [Seeking Alpha]
11/17
06:13 am
fhtx
4DMT Appoints Kristian Humer as Chief Financial Officer [Yahoo! Finance]
Low
Report
4DMT Appoints Kristian Humer as Chief Financial Officer [Yahoo! Finance]
11/7
08:45 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.
Medium
Report
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.
11/6
01:21 pm
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
11/5
09:40 pm
fhtx
Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Challenges Ongoing Loss Narrative [Yahoo! Finance]
Low
Report
Foghorn Therapeutics (FHTX): Forecast 28.8% Revenue Growth Challenges Ongoing Loss Narrative [Yahoo! Finance]
11/5
07:00 am
fhtx
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
High
Report
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
11/3
07:30 am
fhtx
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Medium
Report
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
10/30
07:30 am
fhtx
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
Low
Report
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
10/16
07:00 am
fhtx
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Low
Report
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
9/18
06:44 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Medium
Report
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
9/17
10:08 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at B. Riley. They set a "buy" rating and a $10.00 price target on the stock.
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at B. Riley. They set a "buy" rating and a $10.00 price target on the stock.